The vegetarian food brand has closed an $18.3m round co-led by Vorwerk Ventures and backed by fellow corporate investor Gaydoul Group.
Author: Thierry Heles
Genomics gets its hands on $30m
The Vertex Pharmaceuticals-backed genomic analytics platform developer has now raised approximately $88m in funding altogether.
Carisma charms its way to $59m
Penn Medicine contributed to a $12m extension for the cancer immunotherapy developer’s series B round, which already inlcuded Livzon, Merck & Co and AbbVie.
Shield AI covers $90m series C
Point72 Ventures led a series C round for Bloomberg Beta-backed Shield AI, which will use the cash to expand its drone software product.
Cyteir slides in $80m
Returning backer Novo was among the investors in a series C round for the synthetic cancer treatment developer that was led by RA Capital Management.
Sana Bio plants itself on public markets
The Alphabet-backed immunotherapy developer secured nearly $588m in what was reputedly the largest ever flotation for a preclinical life sciences company.
Resproly inhales $31m in series B round
Gree and Shanghai Kindly-backed, respiratory-focused medical device and drug developer Resproly has closed a round led by CAS Investment Management.
Databricks constructs $1bn series G round
AWS, CapitalG and Salesforce Ventures helped the data management software provider increase its valuation more than fourfold to $28bn.
Sana Bio sets $345m IPO target
The GV-backed stem cell drug developer has set terms for an initial public offering that would raise between $300m and $345m.
Encodia decodes $75m series C
Northpond and Deerfield have co-led a $75m series C round for protein analysis system developer Encodia that included GV and Nan Fung Life Sciences.
Kleo finds a home at Biohaven
Biohaven has purchased the 58% stake cancer immunotherapy developer Kleo Pharmaceuticals it did not already own.
BlueSphere Bio brings in series B funding
UPMC-backed cancer immunotherapy developer BlueSphere Bio has attracted an initial $45.6m in series B funding towards a $105m target for its close.
Sana Bio seeks $150m in IPO
The stem cell therapy developer has filed to go public seven months after closing $700m in funding from investors including Alphabet unit GV.
Werewolf scares up $72m
Taiho Ventures returned for a $72m series B round closed by Werewolf Therapeutics, which is now set to advance two lead oncology assets through phase 1 trials.